Peroxisome proliferator-activated receptor gamma and metabolic disease.
about
Intracellular signalling by C-peptideTranscription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunitMechanisms of phthalate ester toxicity in the female reproductive systemSDP1 is a peroxisome-proliferator-activated receptor gamma 2 co-activator that binds through its SCAN domainParallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgammaSerum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in ratsPPARgamma, neuroinflammation, and diseaseMolecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive MoleculesCould metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?Targeting inflammation in diabetes: Newer therapeutic optionsPPAR-γ -- a possible drug target for complicated pregnanciesInflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targetsLiver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunityAtomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands(+)-Rutamarin as a Dual Inducer of Both GLUT4 Translocation and Expression Efficiently Ameliorates Glucose Homeostasis in Insulin-Resistant MiceGQ-16, a Novel Peroxisome Proliferator-activated Receptor (PPAR ) Ligand, Promotes Insulin Sensitization without Weight GainMedium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial AgonistsPotential of Natural Products in the Inhibition of Adipogenesis through Regulation of PPARγ Expression and/or Its Transcriptional ActivityPPARγ as a therapeutic target to rescue mitochondrial function in neurological diseaseAlzheimer's disease and type 2 diabetes via chronic inflammatory mechanismsPioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic ratsThe peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectinA SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gammaThe ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated micePPARγ Agonists Attenuate Trigeminal Neuropathic Pain.Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome.Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells.Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammationRole of G protein-coupled receptor kinase-2 in peroxisome proliferator-activated receptor gamma-mediated modulation of blood pressure and renal vascular reactivity in SHR.PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.Leptin revisited: its mechanism of action and potential for treating diabetes.Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.Pharmacophore-driven identification of PPARγ agonists from natural sources.Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetesTargeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic DrugsZinc-chelated Vitamin C Stimulates Adipogenesis of 3T3-L1 CellsNovel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system.Thiazolidinediones are partial agonists for the glucocorticoid receptor.The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease.
P2860
Q21342827-90E448C8-9F1F-41E0-814E-EC14D1EA74E5Q24303852-90484D76-D0DA-4849-83CF-7F32B56CE52CQ24529989-8D868436-4AF6-4D2A-AFEB-D3B2B3F65E47Q24535573-1586914C-901E-40AC-8268-C10E08899A63Q24685818-64FC9ED2-3F81-491B-8F95-A247155C9FD6Q24793556-10592743-5587-4DEF-8FD1-CEC36F505555Q24794438-788DC772-7957-4D00-AB74-D7D8C652E9E2Q26770105-495AE3C1-4A48-46F3-9982-1AF9B720FE21Q26824893-C3949B54-637D-4917-B1E4-B3F04CF16D89Q26852726-C8711ECA-70DF-41C4-A779-641F6542C68BQ26863678-B970D819-A3A3-44EC-A67C-E0C0B6C82672Q26866480-91262B73-7406-4A1C-A51D-D2FC685A4F25Q27013011-217E82A4-1B70-4A83-B887-9FA32DF9FB47Q27653218-D902A422-B947-4621-873F-E5A57EDDD291Q27677636-C51DD391-5801-43F4-B890-3F9D040FD4B7Q27679090-20DF977E-42B0-4924-95E3-C4F3705DB9E2Q27679376-92B851ED-7897-42CA-B0CF-AC943FE80ABAQ28066552-E3FE5943-5678-4CE8-B099-4A29EF11A112Q28069549-C1F9A921-5B5C-4B22-9B84-C5FF8B82D909Q28086892-92F89B59-5CDF-4549-A166-6078AAB51408Q28580246-C60BFBD6-C986-4009-8627-60B07D656A2BQ28585701-DE37E067-C40A-4DB3-AC85-902B4C433821Q28593737-A563CB2A-BE6B-43CA-98D3-EC6DE9192870Q28742884-21386576-99D3-4396-A984-386268BF0478Q30006155-EE7C765E-63BA-47AD-9AFD-371A0B7D7716Q30472847-E5C1BD02-52CF-4DD8-8593-308915698431Q33247258-CEE8B751-4A6A-4AC3-AE91-A034DC16F590Q33420391-23C8AFBC-BAFA-4ADE-8096-539D1AC28614Q33440398-99C1A236-A384-4E76-B01D-3EC982730E77Q33572403-50A24C87-11BB-4B1E-810E-B8E7B7754512Q33585657-5E915818-E68E-4CE8-A521-6D7136350E11Q33602487-09B548F3-5D2D-4214-B98F-82ABDF76CDDEQ33727061-2CB7B0B3-9B65-4097-BE7D-8D724C0CE870Q33744181-5EFCECA6-4FF5-4D31-B2CA-778FADB5E48AQ33797616-B4CEDD4A-060C-4E9A-8169-7B303F16579CQ33809886-31949CBA-DF18-434C-8F6E-2A986CF97284Q33885244-B60FD943-B432-4EA5-8CE0-9EF7F7132F0BQ33935032-3E4E4D74-6862-444F-8B42-C7494F142347Q33948063-DC208256-83DA-4DED-8C6E-ADD7B6AE9900Q34035340-D6A7F7E9-7E1A-4AFD-B818-203F964055D8
P2860
Peroxisome proliferator-activated receptor gamma and metabolic disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@ast
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@en
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@nl
type
label
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@ast
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@en
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@nl
prefLabel
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@ast
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@en
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@nl
P2093
P1476
Peroxisome proliferator-activated receptor gamma and metabolic disease.
@en
P2093
Kliewer SA
Lambert MH
Willson TM
P304
P356
10.1146/ANNUREV.BIOCHEM.70.1.341
P577
2001-01-01T00:00:00Z